Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Orthopedics, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Jilin, China.
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1193-1195. doi: 10.1080/14712598.2023.2273276. Epub 2023 Dec 28.
According to recent research, bispecific antibodies (BsAbs) are a promising new immunotherapy method. Various BsAb forms are constantly being developed. In the year 2022 alone, four BsAbs (tebentafusp, faricimab, mosunetuzumab, and teclistamab) were approved for clinical applications. BsAbs including odronextamab, talquetamab, linvoseltamab, and elranatamab are being actively evaluated in different clinical studies. Preliminary results show promising response rates in relapsed/refractory follicular lymphoma (RRFL), relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL), and relapsed/refractory multiple myeloma (RRMM), especially in heavily pretreated patients, including those who have progressed after proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and CAR-T therapies. We summarized data published at the 28th European Hematology Association (EHA) annual meeting, which was held in Frankfurt between 8 June 2023 and 11 June 2023 on BsAbs monotherapy or combination therapy for RRFL, RRDLBCL, and RRMM.
根据最近的研究，双特异性抗体（BsAbs）是一种很有前途的新免疫疗法。各种 BsAb 形式不断被开发出来。仅在 2022 年，就有四种 BsAbs（tebentafusp、faricimab、mosunetuzumab 和 teclistamab）被批准用于临床应用。包括 odronextamab、talquetamab、linvoseltamab 和 elranatamab 在内的 BsAbs 正在不同的临床研究中积极评估。初步结果显示，在复发/难治性滤泡性淋巴瘤（RRFL）、复发/难治性弥漫性大 B 细胞淋巴瘤（RRDLBCL）和复发/难治性多发性骨髓瘤（RRMM）中，反应率有希望，尤其是在经过大量预处理的患者中，包括那些在蛋白酶体抑制剂、免疫调节剂、抗 CD38 抗体和 CAR-T 治疗后进展的患者。我们总结了 2023 年 6 月 8 日至 11 日在法兰克福举行的第 28 届欧洲血液学协会（EHA）年会上发表的关于 BsAbs 单药或联合治疗 RRFL、RRDLBCL 和 RRMM 的数据。
